NCT05463965View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

605

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

January 29, 2023

Study Completion Date

June 15, 2023

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

QM1114-DP

Intramuscular injection

BIOLOGICAL

OnabotulinumtoxinA

Intramuscular injection

BIOLOGICAL

Placebo

Intramuscular injection

Trial Locations (6)

100730

Beijing Tongren Hospital, CMU, Beijing

510317

Guangdong Second Provincial General Hospital, Guangzhou

Unknown

Xiangya 3rd Hospital, Changsha

Zhejiang Provincial People's Hospital, Hangzhou

Peking University First Hospital, Beijing

Tianjin University General Hospital, Tianjin

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT05463965 - A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter